Skip to Main content Skip to Navigation
Journal articles

Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

Abstract : Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-01479198
Contributor : Manon Carré <>
Submitted on : Tuesday, February 28, 2017 - 4:42:01 PM
Last modification on : Wednesday, August 19, 2020 - 12:08:19 PM
Long-term archiving on: : Monday, May 29, 2017 - 4:04:13 PM

File

13760-205433-1-PB.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

María Rico, María Baglioni, Maryna Bondarenko, Nahuel Cesatti Laluce, Viviana Rozados, et al.. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget, Impact journals, 2017, ⟨10.18632/oncotarget.13760⟩. ⟨hal-01479198⟩

Share

Metrics

Record views

245

Files downloads

764